Abstracts tagged "Biomarkers and epigenetics"

Abstract Number: 2804 • 2015 ACR/ARHP Annual Meeting
The Global miRNA Whole Blood Profile of Ankylosing Spondylitis
Carolina Mejia Otero¹, Shervin Assassi¹, Michael H. Weisman², Michael M. Ward³, Lianne S. Gensler⁴, Matthew A. Brown⁵, Minghua Wu¹, John Hagan⁶, John D. Reveille⁷ and Gloria Salazar¹, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Neurosurgery, University of Texas at Houston, Houston, TX, ⁷Internal Medicine/Rheumatology, University of Texas Medical School at Houston, Houston, TX
Background/Purpose: MicroRNA (miRNA) are small non-coding RNAs that play an important role in posttranscriptional gene regulation and their involvement in the pathophysiology of several autoimmune…
Abstract Number: 2594 • 2012 ACR/ARHP Annual Meeting
Epigenetic Signature of the Response to Anti-TNF in Juvenile Idiopathic Arthritis
Roberto Spreafico¹, Maura Rossetti¹, Hong Zhang¹, Maryam Moshref¹, Carol Wallace², D. J. Lovell³ and Salvatore Albani⁴, ¹Translational Immunology, Sanford-Burnham Medical Research Institute, La Jolla, CA, ²Div Rheumatology-Pediatrics, Childrens Hosp & Regional Med, Seattle, WA, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Translational Research Program, Infectious and Inflammatory Diseases, Sanford-Burnham Medical Research Institute, La Jolla, CA
Background/Purpose: The identification of prognostic markers of responsiveness to the therapy in JIA would not only radically improve clinical management, but also shed light on…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.